Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis.
Time limited immunomodulatory functions of transplanted neural precursor cells.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
The little compound that could: how phenytoin changed drug discovery and development.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Cortical lesion load associates with progression of disability in multiple sclerosis.
Memory rehabilitation for people with multiple sclerosis.
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
FDA warns about seizures linked to MS drug
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit

Pages